Do Accelerated Approvals Really Benefit Patients? With Ravi Parikh ...

Recently, Ravi Parikh, MD, MPP, an Assistant Professor of Medical Ethics and Health Policy and Medicine at the University of Pennsylvania, ...

Play Do Accelerated Approvals Really Benefit Patients? With Ravi Parikh, MD, MPP by Oncology Data Advisor® on desktop and mobile.

Exposure to US Cancer Drugs With Lack of Confirmed Benefit After ...

Between 2009 and 2022, the US Food and Drug Administration (FDA) approved 48 drugs for 66 oncology-related indications under the Accelerated ...

How a controversial US drug policy could be harming cancer ...

To understand how others deal with that inclination, Parikh and his colleagues reviewed how doctors responded to the accelerated approval of ...

Penn Medical Ethics and Health Policy | In the News

Do Accelerated Approvals Really Benefit Patients? With Ravi Parikh, MD, MPP. In this interview with OncData, he further discusses his research and gives a ...

Expert Weighs In On New FDA AA Guidance for Cancer - BioSpace

Ravi B. Parikh discussed how new FDA guidance on accelerated approval for cancer drugs will affect the space.

Pembrolizumab Approval Withdrawn for Third-Line Gastric Cancer ...

Do Accelerated Approvals Really Benefit Patients? With Ravi Parikh, MD, MPP. Oncology Data Advisor™ · Do Accelerated Approvals Really Benefit Patients? With ...

Prior Authorization: Changes May Ease the Burden

Health care providers and patients have called the prior authorization process burdensome and noted that it can create barriers to optimal ...

OncData Lyn on X: "Listen into this podcast where @ravi_b_parikh ...

@ravi_b_parikh. provides a thought-provoking ... #program · Do Accelerated Approvals Really Benefit Patients? With Ravi Parikh, MD, MPP - Oncology Data Advisor.

Clinical Benefit and Regulatory Outcomes of Cancer Drugs ...

Main Outcomes and Measures Demonstrated improvement in quality of life or overall survival in accelerated approvals with more than 5 years of ...

Oncologists Respond Swiftly to FDA Safety Alerts, Penn Study Finds

Supporters say it can bring promising drugs into the clinic more quickly, which can benefit millions of patients. Critics say these drugs should ...

US drug approval policy could be harming patients worldwide - Juta ...

Parikh has seen accelerated-approval drugs help his patients to live longer. But he has sometimes felt unsure about the benefits of a newly available drug for a ...

Podcasts - Ravi B. Parikh, MD, MPP

Preparing for the AI-Driven Future of Oncology · Dr. · Malfunction, Malpractice? · Do Accelerated Approvals Really Benefit Patients? · Machine learning helps ...

Studies show oncologists can adapt quickly to new evidence - Healio

“The accelerated approval process, which approves drugs based on phase 2 evidence — noncomparative studies — has come under a lot of scrutiny,” ...

FDA Label Change Takes a Bite Out of Prescriptions - OncLive

Supporters say the accelerated approval program is an important tool to get vital medications to patients quickly. Critics argue that these ...

Ravi B. Parikh - oncology #medicare #payment - LinkedIn

Accelerated approval. We're all about patients getting faster access to treatment. In fact, we've built our very mission around it. The ...

Prior Authorization in Oncology: Burdens and Barriers to Care

Research suggests that prior authorization has negative effects on cancer patients and oncology providers.

Oncologists quickly react to label changes for immunotherapies, a ...

24, come at a time when oncologists have to keep up with the rapid pace of approval of new therapies. This is especially important in the ...

Exposure to US Cancer Drugs With Lack of Confirmed Benefit After ...

... 14 Evidence also suggests that over a quarter of patients with oncology related indications could receive accelerated approval drugs that lack confirmed ...

Exposure to US Cancer Drugs With Lack of Confirmed Benefit After ...

Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug ... Accelerated Approval. JAMA Oncol. 2023 Apr 1;9(4):567-569. doi: ...